A Multicenter Randomized Double-Masked Study Comparing Preservative-free Brimonidine Tartrate Ophthalmic Solution 0.025% with LUMIFY® 0.025% for Ocular Redness in Adults
Abstract Introduction Ocular redness is common, can affect quality of life, and can be relieved by short-term use of topical adrenergic receptor (AR) agonists. Brimonidine tartrate ophthalmic solution 0.025% (LUMIFY® 0.025%) is the first α2-AR-selective agonist approved for ocular redness. The prese...
Saved in:
| Main Authors: | Melissa Toyos, Melinda DiVito, Elisabeth M. Messmer, Selina McGee, Jared Peterson, Assem Patel, Guruprasad Pattar, David G. Evans, Patrick M. Vollmer, Gina Wesley |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2025-07-01
|
| Series: | Ophthalmology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40123-025-01194-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Fabrication of Anti-glaucoma Nanofibers as Controlled-Release Inserts for Ophthalmic Delivery of Brimonidine Tartrate: In Vivo Evaluation in Caprine Eye
by: Fariba Shaikhi Shoushtari, et al.
Published: (2024-07-01) -
Novel Uses of Brimonidine
by: Hikkalagutti. S. Kruthika, et al.
Published: (2024-07-01) -
Efficacy and safety of 0.1 % brimonidine as a starting monotherapy and when added to combination therapy of glaucoma
by: E. D. Semenov, et al.
Published: (2024-12-01) -
Central Nervous System Depression After Topical Administration of Brimonidine Eye Drops to Induce Vomiting in a Cat
by: Dalhae Kim, et al.
Published: (2025-05-01) -
Brimonidine-Soluplus Nanomicelles: Preparation and in-vitro evaluation
by: Noor Al wiswasi, et al.
Published: (2025-03-01)